{"filings":[{"id":900198,"accession_number":"0001193125-26-260671","cik":2042347,"company_name":"Seaport Therapeutics, Inc.","ticker":"SPTX","form_type":"8-K","filed_at":"2026-06-08T11:11:42+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seaport Q1 net loss $25.4M; cash $212.6M; GlyphAgo Ph1 shows liver safety; GlyphAllo Ph2b on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.4M (vs $13.1M YoY); R&D expenses $21.4M, up from $10.5M YoY.","Cash $212.6M at Q1 end; +$260M from May IPO provides runway into 2029.","GlyphAgo Phase 1 MAD data show therapeutic exposures at doses avoiding liver enzyme elevations, no liver AEs.","GlyphAllo Phase 2b BUOY-1 enrollment on track; topline data 1H 2027; driving simulation trial dosed, data 2H 2026.","Sharon Mates appointed to board; upsized IPO raised $260M gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":996392681.43,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97448,"accession_number":"0001193125-26-204086","cik":2042347,"company_name":"Seaport Therapeutics, Inc.","ticker":"SPTX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Seaport Therapeutics adopts new charter authorizing 700M shares, completes IPO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed amended charter authorizing 700M total shares: 500M voting common, 200M non-voting common, 10M undesignated preferred.","Eliminated references to prior preferred stock series; Board may issue undesignated preferred in series.","Adopted amended bylaws with stockholder meeting procedures, advance notice proposals, and director nomination rules.","Charter and bylaw changes became effective upon IPO consummation on May 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":996392681.43,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}